Italia markets close in 32 minutes
FTSE MIB
33.547,40 -159,81 (-0,47%) Dow Jones
39.040,89 -71,27 (-0,18%) Nasdaq
17.765,54 +47,89 (+0,27%) Nikkei 225
39.667,07 +493,92 (+1,26%) Petrolio
80,24 -0,59 (-0,73%) Bitcoin EUR
57.818,13 +62,44 (+0,11%)
NBIX Jul 2024 130.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 03:32PM EDT. Mercato aperto.
| Chiusura precedente | 2,8300 |
| Aperto | 2,6000 |
| Denaro | 0,7000 |
| Domanda | 4,7000 |
| Prezzo d'esercizio | 130,00 |
| Scadenza | 2024-07-19 |
| Min-Max giorno | 2,6000 - 2,8300 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 22 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.